Clinical Trials
3 trialsNCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00401401 2011-12-23
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Genmab
Phase 1/2 Terminated